These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25999706)

  • 1. Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease.
    Fu AZ; Sun SX; Huang X; Amin AN
    Int J Chron Obstruct Pulmon Dis; 2015; 10():909-15. PubMed ID: 25999706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
    Moll K; Sun SX; Ellis JJ; Howe A; Amin A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study.
    Garbe E; Hoti F; Schink T; Svendsen K; Al-Eid H; Arkhammar P; Carlholm M; Fjällbrant H; Franzén S; Hedlund C; Kollhorst B; Kumar A; Lobier M; Mushnikov V; Persson T; Qiao X; Salosensaari A; Schäfer W; Sicignano NM; Johansson G; Dareng EO
    Int J Chron Obstruct Pulmon Dis; 2024; 19():1879-1892. PubMed ID: 39185393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis.
    Yuan L; Dai X; Yang M; Cai Q; Shao N
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1477-83. PubMed ID: 27418821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.
    Wan Y; Sun SX; Corman S; Huang X; Gao X; Shorr AF
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2127-36. PubMed ID: 26504378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roflumilast: Who Is Using It and How It Affects Health Care Resource Utilization and Costs.
    Jain R; Cai Q; Sun SX; Tan H
    Manag Care; 2015 Aug; 24(8):40-8. PubMed ID: 26399141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
    Oba Y; Lone NA
    Ther Adv Respir Dis; 2013 Feb; 7(1):13-24. PubMed ID: 23197074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease.
    Kim KH; Kang HS; Kim JS; Yoon HK; Kim SK; Rhee CK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3449-3456. PubMed ID: 29270006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
    Pinner NA; Hamilton LA; Hughes A
    Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.
    Rennard SI; Sun SX; Tourkodimitris S; Rowe P; Goehring UM; Bredenbröker D; Calverley PM
    Int J Chron Obstruct Pulmon Dis; 2014; 9():657-73. PubMed ID: 25018629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roflumilast (Daliresp) for COPD.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
    Yan JH; Gu WJ; Pan L
    Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.
    Kardos P; Mokros I; Sauer R; Vogelmeier CF
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1455-1468. PubMed ID: 29765213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
    Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
    Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and harms of roflumilast in moderate to severe COPD.
    Yu T; Fain K; Boyd CM; Singh S; Weiss CO; Li T; Varadhan R; Puhan MA
    Thorax; 2014 Jul; 69(7):616-22. PubMed ID: 24347460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
    Wedzicha JA; Rabe KF; Martinez FJ; Bredenbröker D; Brose M; Goehring UM; Calverley PMA
    Chest; 2013 May; 143(5):1302-1311. PubMed ID: 23117188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
    Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
    Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Rabe KF
    Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roflumilast in the management of chronic obstructive pulmonary disease.
    Lipari M; Benipal H; Kale-Pradhan P
    Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.